Middle East Healthcare Company

SASE:4009 Stock Report

Market Cap: ر.س10.3b

Middle East Healthcare Future Growth

Future criteria checks 4/6

Middle East Healthcare is forecast to grow earnings and revenue by 20.6% and 10.8% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be 18.1% in 3 years.

Key information

20.6%

Earnings growth rate

20.8%

EPS growth rate

Healthcare earnings growth14.2%
Revenue growth rate10.8%
Future return on equity18.1%
Analyst coverage

Good

Last updated11 Feb 2024

Recent future growth updates

Recent updates

There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump

Feb 11
There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump

Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled

Feb 08
Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled

Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?

Jan 18
Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?

Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors

Dec 28
Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors

Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends

Sep 26
Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends

Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Jun 28
Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Mar 30
Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal

Sep 20
Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal

Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)

Jun 14
Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)

Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture

Apr 18
Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture

Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Aug 10
Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends

Mar 29
Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends

An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued

Mar 03
An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued

Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 10
Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?

Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock

Jan 23
Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock

If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%

Jan 05
If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%

Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?

Dec 18
Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?

Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)

Nov 30
Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)

Earnings and Revenue Growth Forecasts

SASE:4009 - Analysts future estimates and past financials data (SAR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,7533963474133
12/31/20253,4093452174315
12/31/20243,0342801703176
12/31/20232,649193-1371146
9/30/20232,55117723282N/A
6/30/20232,39313563346N/A
3/31/20232,276105-95172N/A
12/31/20222,15275-17476N/A
9/30/20222,03324-2929N/A
6/30/20222,01927-3091N/A
3/31/20221,96826-259114N/A
12/31/20211,87317-34177N/A
9/30/20211,82345-434-37N/A
6/30/20211,81666-580-160N/A
3/31/20211,73373-501-166N/A
12/31/20201,75182-524-229N/A
9/30/20201,708110-507-182N/A
6/30/20201,603108-348-23N/A
3/31/20201,583104-440-38N/A
12/31/20191,49798-37399N/A
9/30/20191,40191-351133N/A
6/30/20191,35378-335180N/A
3/31/20191,346100-289164N/A
12/31/20181,391172-197159N/A
9/30/20181,445224-39317N/A
6/30/20181,459269-61204N/A
3/31/20181,464297-17135N/A
12/31/20171,462319110347N/A
9/30/20171,503322265370N/A
6/30/20171,529356N/A256N/A
3/31/20171,588368N/A453N/A
12/31/20161,616363N/A253N/A
9/30/20161,629380N/A72N/A
6/30/20161,602371N/A313N/A
3/31/20161,564389N/A303N/A
12/31/20151,535390N/A194N/A
9/30/20151,485373N/A434N/A
6/30/20151,456356N/A383N/A
3/31/20151,431357N/A253N/A
12/31/20141,399332N/A349N/A
12/31/2013828137N/A129N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4009's forecast earnings growth (20.6% per year) is above the savings rate (14%).

Earnings vs Market: 4009's earnings (20.6% per year) are forecast to grow faster than the SA market (6% per year).

High Growth Earnings: 4009's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4009's revenue (10.8% per year) is forecast to grow faster than the SA market (0.6% per year).

High Growth Revenue: 4009's revenue (10.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4009's Return on Equity is forecast to be low in 3 years time (18.1%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.